Luke Timmerman

Another Timmerman Traverse for Life Science Cares is in the books. This year, we raised $1.15 million from more than 1,000 donors to fight poverty in biotech hubs around the US. We raised awareness of worthy nonprofits close to home, through Life Science Cares. Perhaps most importantly, we had an unforgettable life experience, making friends... Read More

Sabah Oney is today’s guest on The Long Run. Sabah is the CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics. This startup is developing engineered CAR-T cell therapies for solid tumors. The goal is to bring the power of CAR-T cell cures to a wider group of patients, beyond those with blood cancers. Dispatch was... Read More

[Editor’s note: this column was first published in Feb. 2022. I’m republishing now because I think the biotech community could use a dose of inspiration.] Every thriving biotech hub can trace its origins to one or two outstanding scientific institutions. But every thriving region can also trace some of its success back to community leaders.... Read More

John Rinn is today’s guest on The Long Run. John is the Leslie Orgel and Marvin Caruthers professor of RNA science at the University of Colorado in Boulder. His research is focused on long non-coding RNAs. This is the vast expanse of the genome that doesn’t contain genes with code for making proteins. Researchers once... Read More

Kathmandu, Nepal We did it together. The Timmerman Traverse for Damon Runyon Cancer Research Foundation completed a splendid expedition to Everest Base Camp on Apr. 23, 2025. This trip succeeded on every count. All 17 members of the team made it to the mountaineering camp at 17,600 feet / 5,364 meters. We exceeded our $700,000... Read More

Times are tough in biotech, but this is an industry where we learn, adapt, and move forward. I’m proud to announce that the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit its fundraising goal of $700,000 to support high-risk / high-reward cancer research. We stand at $702,555 in closed donations. Our team... Read More

David Schenkein is today’s guest on The Long Run. David is a general partner with GV. It’s the non-strategic corporate venture firm formerly known as Google Ventures. GV is backed by a single limited partner, Alphabet, and has $10 billion in assets under management in 400 active portfolio companies working in tech and life sciences.... Read More

I’m excited to announce the 2025 Timmerman Traverse for Damon Runyon Cancer Research Foundation team. This group of 17 men and women are on a mission to raise more than $700,000 for the next generation of outstanding cancer researchers. In April, we’ll come together on the world-famous trek to Everest Base Camp, elevation 17,600 feet.... Read More

Hard to believe, but the 10th Anniversary of Timmerman Report is coming up in March 2025. Time to party! The past 10 years of biotechnology have been remarkable. I’m fortunate. I’ve had a front-row seat to chronicle monumental advances at Timmerman Report, and occasionally influence events. Join me and a group of biotech leaders in... Read More

Happy Veteran’s Day. For some reason, this day doesn’t receive the same level of attention of most holidays on the American calendar. Let’s pause today to thank veterans in our communities. For real. Face to face. Or maybe on the phone. Not in a tweet. As I wrote last year: Today is a day when... Read More